This trial is evaluating whether Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) will improve 2 primary outcomes and 6 secondary outcomes in patients with Malignant Neoplasm of Pancreas. Measurement will happen over the course of Day 0 (Day of insertion).
This trial requires 30 total participants across 1 different treatment group
This trial involves a single treatment. Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"As an incurable disease, a constant change in the pancreas is observed. The pancreatic tissues show a steady change from duct cells, acinar cells to islet cells, each type of cell presents individually in different organs in a different location. Thus, the pancreas seems to be perpetually growing and dividing to generate new components of the pancreas, and also changing into other forms. The endocrine imbalance hypothesis is supported by the facts that acute/chronic pancreatitis is the most common cause of acute pancreatic disease. Also, the change of normal pancreas may have a leading role in pancreatic cancer. What is known about this subject can all be found in this article." - Anonymous Online Contributor
"Pancreatic cancer is a malignant disease that most commonly affects middle-aged men and women. It forms in the glandular tissues of the pancreas and is usually detected at an advanced stage. It is associated with high mortality rates. It is the fourth leading cause of cancer deaths in Japan. Pancreatic cancer has a poor prognosis with an average 5-year survival rate below 10%. Patients need to be carefully monitored for recurrence and signs of recurrence." - Anonymous Online Contributor
"Symptoms of cancer of pancreas are similar to the general signs and symptoms of pancreatic cancer and are similar to the common signs reported by primary health-care practitioners." - Anonymous Online Contributor
"Treatment for an ACC, NSCLC, or other malignancy is similar to treatment of malignancies more common elsewhere in the body. Surgical resection of the tumor and lymph node dissection, with or without adjuvant chemotherapy, should be considered to preserve the remaining pancreas if feasible. Advanced or unresectable disease dictates the use of chemotherapy and biological agents such as bevacizumab and PD-1 inhibitors." - Anonymous Online Contributor
"The number of pancreatic cancers diagnosed in the U.S. population will steadily increase, with an expected increase of 8 in 10 men and 4 in10 women from 2000 to 2030. The age-adjusted rate has not change significantly in the last 65 years." - Anonymous Online Contributor
"Surgery can be considered as an option to cure tumors where a cure is not possible but the patient will be better-off with a surgery than with no treatment." - Anonymous Online Contributor
"Alcohol, smoking, diet, diabetes, and obesity are not the main causes of pancreas cancer. The question is: is tobacco carcinogenesis modified by low sodium diet? answer: Data from a recent study show that low sodium diet is associated with a significant decrease in the risk of pancreatic cancer." - Anonymous Online Contributor
"In the United States, only 1-in-15 patients with pancreatic cancer are thought to receive the treatment currently available. Although this radiotherapy is effective, further improvements are needed." - Anonymous Online Contributor
"[Cancers of the pancreas are difficult to diagnose clinically and are usually diagnosed post-mortem as an resectable tumour after pancreatectomy] Given the challenges in diagnosis, this field is still very limited. Recent breakthroughs involve the use of antibodies against tumour antigens in combination with immunotherapy to tackle tumour cells and their infiltrating inflammatory cells. These antibodies represent possible therapeutic targets to complement resection surgery." - Anonymous Online Contributor
"Data from a recent study shows that dART is more effective in reducing the volume of tumor and improving the local control rate and survival rate of patients with advanced tumors undergoing pancreatic cancer and a single dART dose is safe with a small chance of severe adverse effects." - Anonymous Online Contributor
"For our group of patients, a clinical trial was not considered. It seemed to be more of a chance to get benefit from a new treatment as there was an opportunity of getting cure. The chance of cure in patients with a low (0,1%) risk of relapse are very low and no patient would miss out on a trial, so the clinical trial offer seems not worthwhile in these circumstances." - Anonymous Online Contributor
"Use of Alpha particle emitters, including radon (dart) in the treatment of pancreatic carcinoma is a widely used therapy, but the rationale for the use of alpha emitter sources for the treatment of [pancreatic cancer](https://www.withpower.com/clinical-trials/pancreatic-cancer) needs to be re-examined based on the new information concerning adverse effects of radiation on the hematopoietic system and the possible carcinogenic effects of alpha emitter therapies. These newer data raise new possibilities for the use of radiation therapies in the future management of patients with these metastatic cancers." - Anonymous Online Contributor